Temporomandibular Joint Disorders, Temporomandibular Joint Pain
Conditions
Brief summary
The aim of the study will be to analyze the results of injection treatment in patients diagnosed with temporomandibular joint dysfunction manifested by pain and/or limited jaw mobility. The treatment will consist in the administration of autologous blood products into the cavities of the temporomandibular joints.
Detailed description
The aim of the study is to analyze the results of injection treatment in patients diagnosed with temporomandibular joint dysfunction manifested by pain and/or limited jaw mobility. The analyzed treatment will consist in the administration of autologous blood products into the cavities of the temporomandibular joints. We intend to conduct a prospective study without a control group. Patients suffering from pain in the temporomandibular joints and/or limited jaw mobility, in whom injection treatment is the treatment of choice, and patients in whom first-line therapies (pharmacotherapy, physiotherapy, splint therapy) did not bring the desired results, and intra-articular injections are a generally accepted continuation of the therapeutic protocol. Qualified patients will be treated with autologous blood products (injectable platelet-rich fibrin). Data from specialist literature support the safety and effectiveness of administering the above-mentioned substance to the cavities of the temporomandibular joints. The use of blood products in the form of intra-articular injections is medically justified both in the case of pain in the temporomandibular joints and/or in clinical conditions with limited jaw mobility. Currently available scientific publications on the comparison of the effectiveness of therapy with the use of various autologous substances are not numerous and do not give a clear answer to the question of what therapeutic protocol (type of substance, dose, number of administrations, joint compartment) is the most effective in the given observation period. This study aims to clarify some of these issues in regard to the above-mentioned blood product, and thus to obtain valuable clinical data that may help clinicians in choosing the appropriate use of intra-articular injections in patients with temporomandibular joint dysfunction.
Interventions
PROCEDUREI-PRF injection
Intra-articular I-PRF injection to temporomandibular joint cavity
Sponsors
Hospital of the Ministry of Interior, Kielce, Poland
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
We do not choose to create a placebo group or treatment groups other than intra-articular injections. In qualified patients, the administration of the substance into the temporomandibular joint cavity will be the treatment of choice or the generally accepted continuation of therapy in which the first-line treatment (pharmacotherapy, physiotherapy, splint therapy) turned out to be ineffective.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age over 18; * informed consent to participate in the study; * the possibility of discontinuing the current treatment of the temporomandibular joints; * generally accepted indications for injection therapy.
Exclusion criteria
* bleeding diathesis; * mental illness; * temporomandibular joint prosthesis; * temporomandibular joint ankylosis; * skin disease of the preauricular area of the affected side.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Articular pain | 0 - 6 months | Temporomandibular joint pain intensity on Visual Analogue Scale (form 0 - no pain to 10 - worst pain) |
| Mandibular mobility | 0 - 6 months | Range of mandibular abduction (between incisal edges, in mm) |
Countries
Poland
Outcome results
None listed